Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance
Source: SeekingAlpha
2025-12-05 08:06:38 ET
More on Intensity Therapeutics
- Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript
- Intensity Therapeutics announces pricing of $4M registered direct offering of common stock
- Intensity Therapeutics surges 395% on phase 1/2 data for solid tumors asset
- Seeking Alpha’s Quant Rating on Intensity Therapeutics
- Historical earnings data for Intensity Therapeutics
Read the full article on Seeking Alpha
For further details see:
Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance
Intensity Therapeutics Inc.
NASDAQ: INTS
INTS Trading
-1.4% G/L:
$7.7108 Last:
9,945 Volume:
$7.844 Open:
INTS Latest News
March 06, 2026 07:47:00 am
Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
January 13, 2026 07:47:00 am
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
December 11, 2025 07:47:00 am
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
INTS Stock Data
$22,494,329
52,797,104
0.19%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
Shelton
